A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure - Trial NCT05659264
Access comprehensive clinical trial information for NCT05659264 through Pure Global AI's free database. This Phase 1 trial is sponsored by ModernaTX, Inc. and is currently Recruiting. The study focuses on Chronic Heart Failure. Target enrollment is 98 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
ModernaTX, Inc.
Timeline & Enrollment
Phase 1
Nov 18, 2022
May 07, 2024
Primary Outcome
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Summary
The primary objective of this study is to evaluate the safety and tolerability of single and
 multiple doses at escalating dose levels of mRNA-0184.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05659264
Non-Device Trial